#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Primary amyloidosis Chronic lymphocytic leukaemia refractory Diffuse large B-cell lymphoma Epileptic encephalopathy Measles Optic glioma Metachromatic leukodystrophy Brain injury Obesity Round cell liposarcoma Scleroderma associated digital ulcer Oesophageal adenocarcinoma stage III Leber's congenital amaurosis Autoinflammation with infantile enterocolitis Idiopathic inflammatory myopathy More trials…

    Learn about Rare Diseases

    Atypical teratoid/rhabdoid tumour of CNS – Treatment Haemophilia B with anti factor IX – Basic Information Cystic fibrosis – Treatment Niemann-Pick disease – Diagnostics Hereditary motor and sensory neuropathy – Treatment Activated PI3 kinase delta syndrome – Basic Information Systemic mastocytosis – Diagnostics Antisynthetase syndrome – Diagnostics Bronchiolitis obliterans syndrome – Diagnostics Mantle cell lymphoma stage III – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Heparin Calcium Guanabenz Acetate GSKVX000000070965 HUMAN COAGULATION FACTOR XIII Heparin Sodium Sym025 18F-Fludarabine Vh4524184 Soya-Bean Oil Refined Glycerol Phenylbutyrate TX000045 L-Histidine Tafamidis Hexaminolevulinate Pralsetinib Peposertib Autologous Microfat Selexipag TROFOLASTAT Afm24 More therapies…

    Learn about Your Condition

    Labour induction Hypercholesterolaemia Trigeminal neuralgia Atrial flutter Tooth loss Multiple sclerosis relapse Bacterial prostatitis Stevens-Johnson syndrome Nephropathy Pancreatitis acute Anal squamous cell carcinoma PIK3CA-activated mutation Biliary cancer metastatic Leber's congenital amaurosis Shock More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Triple negative breast cancer

  • Study on the Effectiveness of Carboplatin and Olaparib for Patients with Triple-Negative Breast Cancer with Positive HRD Status

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Carboplatin
    • Cyclophosphamide
    Austria

  • Study of JK08, Pembrolizumab, and Lenvatinib for Patients with Advanced or Metastatic Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Thyroid cancer
    • Transitional cell cancer of the renal pelvis and ureter
    • Malignant melanoma
    Investigated Drugs:
    • Jk08
    • Lenvatinib
    • Pembrolizumab
    Belgium Spain

  • Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer metastatic
    • Triple negative breast cancer
    Investigated Drugs:
    • Oleclumab
    • Carboplatin
    • Durvalumab
    Belgium France

  • Study to Improve Tolerance of Sacituzumab Govitecan with Loperamide and Filgrastim in Patients with Advanced Triple-Negative or Luminal Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    • Hormone receptor positive breast cancer
    Investigated Drugs:
    • Loperamide Hydrochloride
    • Sacituzumab Govitecan
    • Filgrastim
    Spain

  • Study of Capivasertib and Paclitaxel for Patients with Advanced or Metastatic Triple-Negative Breast Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Capivasertib
    • Paclitaxel
    Spain

  • Study on Atezolizumab and Drug Combinations for Advanced Malignancies in Patients from Previous Atezolizumab Trials

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    • Metastatic malignant melanoma
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Alectinib
    • Alectinib Hydrochloride
    • Cobimetinib
    Belgium Czechia France Germany Greece Hungary +5
Previous Page
1 … 8 9 10 11 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!